Cardiomyopathies Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$10995
Buy Report View Sample

Published: June 01, 2022 Report Code: GDHC247PIDR-ST

Select Item

Cardiomyopathies market size was approximately $1.6 billion across the 7MM in 2021. The market is expected to grow at a CAGR of more than 12% during the forecast period. The US is the most significant contributor to that revenue.

Cardiomyopathies Market Outlook

Cardiomyopathies Market Outlook

For more insights on cardiomyopathies market forecast, download a free sample

What are the major drivers of the cardiomyopathies market?

Major drivers of the cardiomyopathies market during the forecast period include Camzyos’ market launch as the first drug to target obstructive HCM and the launch of Aficamten. Aficamten is a drug with the same mechanism of action as Camzyos, which should more closely target the pathophysiology of cardiomyopathy. Entresto’s label expansion to include cardiomyopathy, although the drug is already used globally off-label to manage the disease. There are improvements in genetic screening and genetic therapy options.

Which are the key countries in the cardiomyopathies market?

The key countries in the cardiomyopathies market are the US, France, Germany, Italy, the UK, Spain and Japan. The US has the highest sales in the cardiomyopathies market.

Cardiomyopathies market, by key countries

Cardiomyopathies market, by key countries

For more country insights, download a free report sample

What are the key subtypes in the Cardiomyopathies market?

The key subtypes in the Cardiomyopathies market are DCM, HCM, RCM, and ARCM. In 2021, DCM and HCM were the most common cardiomyopathy subtypes in the 7MM.

Cardiomyopathies market, by subtypes

Cardiomyopathies market, by subtypes

For more subtype insights, download a free report sample

Diagnosed Prevalent Cases of Cardiomyopathies by Etiology

The two segments in the diagnosed prevalent cases of cardiomyopathies by etiology are acquired and familial. The most diagnosed cases of cardiomyopathies in the 7MM were acquired in 2021.

Cardiomyopathies market, by etiology

Cardiomyopathies market, by etiology

For more etiology insights, download a free report sample

Diagnosed Prevalent Cases of Dilated Cardiomyopathy by Ischemia

The two key segments in the diagnosed prevalent cases of cardiomyopathies by ischemia are Ischemic and non-ischemic.  In 2021, most diagnosed DCM cases in the 7MM were non-ischemic.

Cardiomyopathies market, by Ischemia

Cardiomyopathies market, by Ischemia

For more Ischemia insights, download a free report sample

Market report overview

Market size 2021 $1.6 billion
CAGR % 12%
Key countries The US, France, Germany, Italy, The UK, Spain and Japan
Key subtypes DCM, HCM, RCM, and ARCM
Key etiology Acquired and Familial
Key Ischemia Ischemic and Non-Ischemic

Scope

  • Overview of cardiomyopathies including epidemiology, disease etiology and management.
  • Topline cardiomyopathy drugs market revenue (including off-label adjunct therapeutics used for metabolic benefits), annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.
  • Key topics covered include assessment of current and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU, and Japan over the 10-year forecast period.
  • Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global cardiomyopathy therapeutics market. Insightful review of the key industry drivers, restraints and challenges.

Key Highlights

The cardiomyopathies market is currently highly genericized and contains many off-label medications, which provide affordable options with limited side effects. These factors create a stiff barrier for entry of novel therapeutics, but pipeline therapeutics will find success due to strong efficacy and safety profiles and that they are cardiomyopathy-specific therapeutics, rather than general cardiovascular drugs.

There is an increased focus on genetic screening and developing genetic therapeutics because cardiomyopathies are often inherited rather than acquired. Emprumapimod will be the first marketed genetic therapy, as it targets patients with DCM due to a lamin gene mutation. However, this drug will not generate significant revenue given the small size of the target patient population.

There is not a cure for cardiomyopathies, instead the disease symptoms are managed with generic cardiovascular drugs. This remains an area of unmet need in the cardiomyopathies space.

Camzyos was the first novel therapy launched in the cardiomyopathies market in several decades when it was marketed in 2022. Thus, there is a need for novel therapies in this space, which should be met by the extensive pipeline.

Reasons to Buy

The report will enable you to:

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.

  • Develop business strategies by understanding the trends shaping and driving the global cardiomyopathy therapeutics market.

  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global cardiomyopathies market in the future.

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

  • Track drug sales in the global cardiomyopathy therapeutics market from 2021-2031.

  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

AstraZeneca
Merck
Boehringer Ingelheim
Novartis
Sanofi
Abbott
GlaxoSmithKline
Bristol Myers Squibb
MyoKardia
Pfizer
Cytokinetics

Table of Contents

| About GlobalData

1 Cardiomyopathies: Executive Summary

1.1 The cardiomyopathies market will experience significant growth between 2021 and 2021

1.2 Label expansion is a current and future growth strategy for companies in the cardiomyopathies space

1.3 Curative therapy options and improvements in genetic screening remain areas of need

1.4 Camzyos to drive cardiomyopathy sales during the forecast period

1.5 What do physicians think?

2 Introduction

2.1 Catalyst

2.2 Related reports

3 Disease Overview

3.1 Etiology and pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

4 Epidemiology

4.1 Disease Background

4.1.1 Risk Factors and Comorbidities

4.2 Global and Historical Trends

4.3 Forecast Methodology

4.3.1 Sources

4.3.2 Forecast Assumptions and Methods

4.3.3 Diagnosed Prevalent Cases of Dilated Cardiomyopathy

4.3.4 Diagnosed Prevalent Cases of Hypertrophic Cardiomyopathy

4.3.5 Diagnosed Prevalent Cases of Restrictive Cardiomyopathy

4.3.6 Diagnosed Prevalent Cases of Arrhythmogenic Cardiomyopathy

4.3.7 Diagnosed Prevalent Cases of Cardiomyopathies by Etiology

4.3.8 Diagnosed Prevalent Cases of Dilated Cardiomyopathy with Ischemia

4.4 Epidemiological Forecast for Cardiomyopathies (2021–2031)

4.4.1 Diagnosed Prevalent Cases of Cardiomyopathies

4.4.2 Diagnosed Prevalent Cases of Cardiomyopathies by Subtype

4.4.3 Age-Specific Diagnosed Prevalent Cases of Cardiomyopathies

4.4.4 Sex–Specific Diagnosed Prevalent Cases of Cardiomyopathies

4.4.5 Diagnosed Prevalent Cases of Cardiomyopathies by Etiology

4.4.6 Diagnosed Prevalent Cases of Dilated Cardiomyopathy with Ischemia

4.5 Discussion

4.5.1 Epidemiological Forecast Insight

4.5.2 COVID-19 Impact

4.5.3 Limitations of the Analysis

4.5.4 Strengths of the Analysis

5 Disease Management

5.1 Diagnosis and treatment overview

5.2 KOL insights on disease management

6 Competitive Assessment

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Improvements in genetic screening and gene therapies

7.3 Curative rather than preventative therapy options

7.4 Newer drugs with specific targets

7.5 Adequate diagnosis and treatment of amyloid cardiomyopathy patients

8 R&D Strategies

8.1 Overview

8.1.1 Label expansion

8.1.2 Development of drugs with novel targets

8.2 Clinical trial design

8.2.1 Quality of life endpoints

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive assessment

11 Current and Future Players

11.1 Overview

11.2 Deal-making trends

12 Market Outlook

12.1 Global markets

12.1.1 Forecast

12.1.2 Drivers and barriers – global issues

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key events

12.3.3 Drivers and barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key events

12.4.3 Drivers and barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting methodology

13.4 Primary research – KOLs interviewed for this report

13.4.1 KOLs

13.5 Primary Research – Prescriber Survey

13.6 About the Authors

13.6.1 Analyst

13.6.2 Therapy Area Director

13.6.3 Epidemiologist

13.6.4 Reviewer

13.6.5 Global Director of Therapy Analysis and Epidemiology

13.6.6 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

Table

Table 1: Cardiomyopathies: Key Metrics in the 7MM

Table 2: Cardiomyopathies: Features and factors

Table 3: Risk factors and comorbidities for cardiomyopathies

Table 4: Most commonly used guidelines for cardiomyopathies by country

Table 5: Pfizer Portfolio Assessment, 2022

Table 6: Bristol Myers Squibb Portfolio Assessment, 2022

Table 7: Cytokinetics Portfolio Assessment, 2022

Table 8: Cardiomyopathies market – global drivers and barriers, 2021–2031

Table 9: Key events impacting sales for cardiomyopathies in the US, 2021–2031

Table 10: Cardiomyopathies Market – Drivers and Barriers in the US, 2021–2031

Table 11: Key events impacting sales for cardiomyopathies in the 5EU, 2021–2031

Table 12: Cardiomyopathies market – drivers and barriers in the 5EU, 2021–2031

Table 13: Key events impacting sales for cardiomyopathies in Japan, 2021–2031

Table 14: Cardiomyopathies market – drivers and barriers in Japan, 2021–2031

Table 15: High-prescribing physicians (non-KOLs) surveyed, by country

Figures

Figure 1: Global sales forecast by country for cardiomyopathies in 2021 and 2031

Figure 2: Analysis of the company portfolio gap in cardiomyopathies during the forecast period

Figure 3: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of cardiomyopathies during the forecast period

Figure 4: Physical differences between a normal heart and hearts afflicted with dilated, hypertrophic, and restrictive cardiomyopathies

Figure 5: 7MM, diagnosed prevalence of cardiomyopathies (%), men and women, all ages, 2021

Figure 6: Sources used and not used for diagnosed prevalent cases of dilated cardiomyopathy

Figure 7: Sources used and not used for diagnosed prevalent cases of hypertrophic cardiomyopathy

Figure 8: Sources used for diagnosed prevalent cases of restrictive cardiomyopathy

Figure 9: Sources used for diagnosed prevalent cases of arrhythmogenic cardiomyopathy

Figure 10: Sources used for diagnosed prevalent cases of dilated cardiomyopathy by etiology

Figure 11: Sources used for diagnosed prevalent cases of hypertrophic cardiomyopathy by etiology

Figure 12: Sources used for diagnosed prevalent cases of restrictive cardiomyopathy by etiology

Figure 13: Sources used for diagnosed prevalent cases of arrhythmogenic cardiomyopathy by etiology

Figure 14: 7MM, diagnosed prevalent cases of cardiomyopathies in 2021, men and women, N, all ages

Figure 15: 7MM, diagnosed prevalent cases of cardiomyopathies by subtype, men and women, all ages, N, 2021

Figure 16: 7MM, age-specific diagnosed prevalent cases of cardiomyopathies, men and women, all ages, N, 2021

Figure 17: 7MM, diagnosed prevalent cases of cardiomyopathies by sex, all ages, N, 2021

Figure 18: 7MM, Diagnosed Prevalent Cases of Cardiomyopathies by Etiology, Men and Women, All Ages, N, 2021

Figure 19: 7MM, diagnosed prevalent cases of ischemic dilated cardiomyopathy, men and women, all ages, N, 2021

Figure 20: Sample cardiomyopathy treatment paradigm

Figure 21: Unmet needs and opportunities in cardiomyopathy

Figure 22: Overview of the development pipeline in cardiomyopathies

Figure 23: Key late-stage trials for the promising pipeline agents that GlobalData expects to be licensed for cardiomyopathy in the 7MM during the forecast period

Figure 24: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of cardiomyopathies during the forecast period

Figure 25: Competitive assessment of the marketed and pipeline drugs benchmarked against the standard of care: ACE inhibitors, ARBs, ARNi (Entresto), beta blockers, MRAs, SGLT2 inhibitors, antiarrhythmics, and calcium channel blockers

Figure 26: Analysis of the company portfolio gap in cardiomyopathies during the forecast period

Figure 27: Deal-Making Trends, 2017–2021

Figure 28: Global (7MM) sales forecast by country for cardiomyopathies in 2021 and 2031

Figure 29: Sales forecast by class for cardiomyopathies in the US in 2021 and 2031

Figure 30: Sales forecast by class for cardiomyopathies in the 5EU in 2021 and 2031

Figure 31: Sales forecast by class for cardiomyopathies in Japan in 2021 and 2031

Frequently asked questions

Cardiomyopathies Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031 standard reports
Currency USD
$10,995

Can be used by individual purchaser only

Most Popular
$21,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Cardiomyopathies Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Cardiovascular reports
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Pharmaceuticals
New
Generic Drugs - Physician Perspective - Thematic Intelligence
$1,495 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Cardiomyopathies Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031 in real time.

  • Access a live Cardiomyopathies Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more